Advanced or recurrent digestive cancer and Endocrine Organic Cancer
Conditions
Interventions
Vaccination of survivin-2B peptide mixed with IFA every 2 weeks
Vaccination of survivin-2B peptide mixed with IFA every 2 weeks, and IFN-alpha twice a week
Vaccination of survivin-2B peptide mixed wi
Sponsors
Department of Surgery, Sapporo Medical University School of Medicine
Department of Pathology Sapporo Medical University, School of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients enrolled in this study were required to conform to the following criteria: (1) to have histologically confirmed digestive cancer and endocrine organic cancer, (2) to be HLA-A*2402 positive, (3) to be survivin-positive in the carcinomatous lesions by immunohistochemistry, (4) to be between 20 and 85 years old, (5) to be unresectable advanced cancer or recurrent cancer, (6) to have Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 2.
Exclusion criteria
Exclusion criteria: Exclusion criteria included (1) the presence of other cancers that might influence the prognosis, (2) immunodeficiency or a history of splenectomy, (3) need of steroid therapy, (4) severe cardiac insufficiency, acute infection, or hematopoietic failure, (5) prior cancer therapy such as chemotherapy, radiation therapy, steroid therapy, or other immunotherapy within the past 4 weeks, (6) ongoing breast-feeding, and (7) unsuitability for the trial based on clinical judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of adverse effect | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of immunological and clinical responses. Immunological responses were investigated by DTH, tetramer staining, and ELISPOT assay. Clinical responses were evaluated by RECIST criteria and change of tumor marker levels. | — |
Countries
Japan
Contacts
Public ContactYuji Iwayama
Sapporo Medical University Department of Surgery
Outcome results
None listed